A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
In the past, there was no second-line chemotherapeutic agent suitable for use when urothelial carcinoma (UC) progressed to platinum-resistant UC. However, recently, several new treatment options, such as immune checkpoint inhibitors or targeted therapy have shifted the treatment paradigm regarding s...
| Published in: | Investigative and Clinical Urology |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Association
2022-07-01
|
| Subjects: | |
| Online Access: | https://www.icurology.org/pdf/10.4111/icu.20220061 |